Investors Connect Biopharma is a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with inflammatory diseases. Press Releases September 10, 2024 Connect Biopharma to Participate in the Cantor Fitzgerald Global Healthcare Conference 2024 September 5, 2024 Connect Biopharma Reports First Half 2024 Financial Results and Provides Business Update July 1, 2024 Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum FRONT >> News > View All View all press releases Latest Events H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference (Skin Diseases, Conditions and Disorders) March 28, 2024 Connect Biopharma Announces Topline Data from Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma December 12, 2023 at 8:30 AM EST Long-Term Data from Rademikibart Atopic Dermatitis China Pivotal Trial November 21, 2023 at 8:30 AM EST FRONT > Events - View All View all events Stock Quote Change Volume Today's Open Previous Close Data Provided by Refinitiv. Minimum 15 minutes delayed. FRONT >> Stock > View All View detailed stock information
September 10, 2024 Connect Biopharma to Participate in the Cantor Fitzgerald Global Healthcare Conference 2024
September 5, 2024 Connect Biopharma Reports First Half 2024 Financial Results and Provides Business Update
July 1, 2024 Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum
H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference (Skin Diseases, Conditions and Disorders) March 28, 2024
Connect Biopharma Announces Topline Data from Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma December 12, 2023 at 8:30 AM EST
Long-Term Data from Rademikibart Atopic Dermatitis China Pivotal Trial November 21, 2023 at 8:30 AM EST
